This segment focuses on the research, development, and commercialization of innovative cancer therapies. Sorrento leverages its proprietary G-MAB antibody library and targeted delivery modalities, including CAR-T cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as bispecific antibody approaches. Research and development activities include preclinical studies, clinical trials, and regulatory submissions for various cancer indications. The company aims to improve patient outcomes by developing therapies that specifically target cancer cells while minimizing side effects. Market positioning is based on the development of next-generation treatments. Future opportunities include expanding the pipeline with novel antibody-based therapies and exploring collaborations to accelerate drug development. Regulatory and clinical aspects involve navigating FDA approval processes and conducting clinical trials to demonstrate safety and efficacy. Partnerships with research institutions and other companies are crucial for advancing the oncology pipeline.

This segment is dedicated to developing and commercializing treatments for pain management, with a focus on non-opioid alternatives. Key activities include the development of resiniferatoxin (RTX), a non-opioid-based TRPV1 agonist neurotoxin for late-stage cancer and osteoarthritis knee pain treatment, and ZTlido, a lidocaine delivery system for postherpetic neuralgia. The segment also includes the development of SEMDEXA, an injectable viscous gel formulation for sciatica, and SP-103, a non-aqueous lidocaine topical system for chronic low back pain. The goal is to provide effective pain relief while minimizing the risks associated with opioid use. Market positioning is based on providing innovative pain management solutions. Future opportunities include expanding the product portfolio and securing regulatory approvals for new indications. Regulatory and clinical aspects involve conducting clinical trials to demonstrate safety and efficacy and obtaining FDA approval. Partnerships with healthcare providers and pharmaceutical companies are essential for commercialization and market access.

This segment focuses on developing therapies to combat infectious diseases, including viral infections. Sorrento has been actively involved in developing antibody-based therapies and vaccines, particularly in response to the COVID-19 pandemic. Research and development activities include collaborations with partners like SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccines and Celularity, Inc. for clinical studies. The segment aims to provide effective treatments and preventative measures against infectious diseases. Market positioning is based on developing innovative solutions to address unmet medical needs. Future opportunities include expanding the pipeline to address emerging infectious diseases and leveraging partnerships to accelerate drug development. Regulatory and clinical aspects involve conducting clinical trials and navigating regulatory approval processes. Collaborations with research institutions and pharmaceutical companies are crucial for advancing the infectious disease pipeline.